IMPROVE‐T2D showed significant early improvements in body weight, body fat, percent insulin sensitivity and secretion and glycemic control at 3 months post VSG, with most participants no longer requiring diabetes medications by 3 months following VSG [17]. This evidence concerns the gene INS and type 2 diabetes mellitus.